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Abstract DNA-dependent protein kinase (DNA-PK) is com- 
posed of a 460-kDa catalytic component (p460) and a DNA- 
binding component Ku protein. Immunoblot analysis after 
treatment of Jurkat cells with anti-Fas antibody demonstrated 
the cleavage of p460 concomitantly with an increase in CPP321 
Yama/apopain activity. Recombinant CPP32/Yamalapopain 
specifically cleaved p460 in the DNA-PK preparation that had 
been purified from Raji cells into 230- and 160-kDa polypep- 
tides, the latter of which was detected in anti-Fas-treated Jurkat 
cells. The regulatory component Ku protein was not significantly 
affected by CPP32/Yama/apopain. DNA-PK activity was 
decreased with the disappearance of p460 in the incubation of 
DNA-PK with CPP32/Yama/apopain. These results suggest hat 
the catalytic component of DNA-PK is one of the target proteins 
for CPP32/Yama/apopain in Fas-mediated apoptosis. 
recently reported that several nuclear autoantigens including 
poly(ADP-ribose) polymerase, U1 snRNA-70 kDa and DNA-  
PKcs are cleaved early during apoptosis in UV-irradiated 
HeLa cells. Poly(ADP-ribose) polymerase that seems to be 
involved in DNA repair has recently been reported to be a 
potential substrate for apopain, also called CPP32 or Yama, 
under the apoptotic process [24-26]. Since the human Jurkat 
T cell line exhibits typical apoptosis after treatment with Fas 
ligand or an agonistic anti-Fas antibody [27], we examined the 
possibility that DNA-PKcs is one of the death substrates dur- 
ing Fas-mediated apoptosis in the Jurkat T cell line. 
Here we show that DNA-PKcs was cleaved on incubation 
with recombinant apopain in vitro as well as during Fas- 
mediated apoptosis in Jurkat cells. 
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1. Introduction 
DNA-dependent protein kinase (DNA-PK) is composed of 
a 460-kDa catalytic subunit tentatively termed DNA-PKcs [1] 
and a DNA-binding component Ku protein (p70/p80) [2-4]. 
DNA-PK  requires double-stranded DNA for the phosphory- 
lation of a variety of replication/transcription factors, such as 
Spl, p53, c-Myc and RP-A [5-13], which likely contain X-S/ 
T-Q or P-S/T-X as minimal requirement for the recognition 
sequence [4]. It has recently been revealed that DNA-PK  is 
involved at least in DNA double-strand break repair and 
V(D)J recombination [14-20], the molecular mechanism of 
which is not fully understood. DNA-PKcs is a member of 
the PI3-kinase superfamily and DNA-PK  activity is sensitive 
to wortmannin, a potent inhibitor of PI3-kinase. DNA-PK,  
however, has no lipid kinase activity [1]. Take et al. [21,22] 
reported a specific inhibitor for DNA-PK,  which is competi- 
tive to ATP and structurally different from wortmannin. 
Based on these attractive properties of DNA-PK,  DNA-PK  
has been considered to function in regulating cell growth, cell 
differentiation or cell maintenance. We detected preliminarily 
limited degradation products of DNA-PKcs in peripheral 
blood lymphocytes or T lymphocytes after growth stimulation 
(Suwa et al., unpublished results). Casciola-Rosen et al. [23] 
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2. Materials and methods 
2.1. Antibodies and chemicals 
Anti-human Fas antibody (clone CH-11) was purchased from Im- 
munotech, Marseille, France. Rabbit anti-DNA-PKcs antibody was 
from Serotech, Oxford, UK. D'-a2p]ATP (3000 Ci/mmol) was pur- 
chased from NEN (Wilmington, DE, USA). Ac-DEVD-AMC, a sub- 
strate for apopain and Ac-DEVD-CHO, an inhibitor of apopain [26] 
were from the Peptide Institute, Inc., Osaka, Japan. 
2.2. Cell culture and preparation of cell-free xtracts 
A human leukemic T cell line, Jurkat, was kindly provided by 
Professor K. Yamamoto in our Institute and was maintained in 
RPMI-1640 medium supplemented with 10% heat-inactivated fetal 
bovine serum as described previously [28]. The cells were incubated 
with anti-Fas antibody (100 ng/ml) at a density of 4x 10 s cells/ml. 
Cell viability was examined by the trypan blue dye-exclusion test. At 
the indicated times, cells were collected and washed once with phos- 
phate-buffered saline. To 5 x 106 cells was added 100 ~tl buffer B (20 
mM Tris-HC1, pH 7.9, 1 mM dithiothreitol, 0.2 mM EDTA, 10% 
glycerol and 1 ~tg ml -I each of aprotinin, leupeptin A and pepstatin) 
containing 0.4 M KC1 as described [4]. After standing on ice for 10 
min, the mixture was centrifuged in an Eppendorf tube at 15 000 rpm 
for 15 min to obtain whole cell extracts. 
2.3. Analysis of DNA fragmentation 
The analysis of oligonucleosomal DNA fragments was performed 
essentially as in [29]. Briefly, the pellet of 106 cells in a Eppendorf tube 
was suspended in 20 ~1 of 50 mM Tris-HC1 (pH 8), 10 mM EDTA, 
0.5% sodium lauryl sarkosinate and 10 ktg proteinase K. The mixture 
was incubated at 50°C for 1 h, and after addition of 5 Ixg RNase A the 
incubation continued for a further 1 h. To the lysate heated to 70°C 
was added 10 I11 of pre-heated 1% low-melt agarose containing 50 mM 
Tris-HC1 (pH 8), 10 mM EDTA, 0.25% bromophenol blue and 40% 
sucrose. The mixed sample was loaded into a dry well on a 2% agar- 
ose gel containing 1 ~tg m1-1 ethidiurn bromide and 0.5 X TBE. After 
electrophoresis in 0.5 × TBE, DNA was visualized under UV light. 
2.4, Assay of apopain 
Apopain activity was fluorometrically determined with Ac-DEVD- 
AMC as a specific substrate [26]. An aliquot of whole cell extracts (2.5 
All rights reserved. 
and 5 p.1) was incubated in a 100/.tl reaction mixture containing 50 
mM Tris-HC1 (pH 7.5), 2 mM dithiothreitol, 250 IxM Ac-DEVD- 
AMC and 10% glycerol at 30°C for 20 min. After addition of 2.9 
ml H20, the product was determined in a Hitachi F-2000 fluorescence 
spectrophotometer at an excitation wavelength of 380 nm and an 
emission wavelength of460 nm. 
2.5. Purification of DNA-PK 
DNA-PK was partially purified from Raji nuclear extracts as de- 
scribed previously [4] and subsequently subjected to glycerol gradient 
(15-30%) centrifugation. The DNA-PK preparation containing DNA- 
PKcs and Ku protein was separated from free Ku. These purification 
procedures will be published in detail elsewhere. 
2.6. Assay of DNA-PK 
DNA-PK activity was determined with either a synthetic peptide 
15, EPPLSQEAFADLWKK, or a-casein as described previously [4] 
except that 300 laM ATP (0.1 laCi [7-32p]ATP) was used for peptide 15 
and 50 ~tM ATP (0.2 ~tCi [7-32p]ATP) for a-casein. Mutant peptide 
15, EPPLSEEAFADLWKK, was used as a negative control [21]. The 
enzyme activity was expressed aspmol Pi incorporated into substrate 
per min at 30°C. 
2. 7. Treatment of DNA-PK with recombinant apopain 
The purified DNA-PK was incubated with recombinant apopain 
[30] at 30°C for 30 min in a reaction mixture (20 ~tl) containing 50 
mM Tris-HCl (pH 7.5), 2 mM dithiothreitol and 10% glycerol. When 
necessary, 0.2 ~tl 10 mM Ac-DEVD-CHO was added to the reaction 
mixture. For assay of DNA-PK, 5-/al portions were taken from the 
reaction mixtures, and residues were subjected toSDS-polyacrylamide 
gel electrophoresis. 
2.8. Western blot~enzyme immunoassay of DNA-PK 
The samples were subjected to electrophoresis on 0.1% SDS/7.5% 
polyacrylamide g l and then blotted onto a nitrocellulose paper. The 
paper was blocked with 1% casein in TBS/Tween 20 (20 mM Tris- 
HCI, pH 7.4/0.15 M NaCI/0.05% Tween 20). The paper was incubated 
with either 1000-fold iluted rabbit anti-DNA-PKcs erum or anti-Ku 
serum from a patient (OM) [31] for 1 h, and then with 1000-fold 
diluted peroxidase-conjugated second antibody against rabbit IgG 
(Bio-Rad) or human IgG (Sigma) in TBS/Tween 20 containing 1% 
casein for 30 min. After washing with TBS/Tween 20, the antigen- 
antibody complex was visualized with a Konica immunostain assay 
kit (Konica, Tokyo, Japan). 
2.9. Protein determination 
Protein was determined by the method of Bradford [32] with bovine 
serum albumin as a standard. Silver staining after SDS-polyacryl- 
amide gel electrophoresis was performed with a kit from Wako 
Pure Chemicals, Osaka, Japan. 
3. Results 
Whole cell extracts from Jurkat cells treated with anti-Fas 
antibody for 0, 2, 4 and 6 h were analyzed by Western blot/ 
enzyme immunoassay with rabbit anti-DNA-PKcs antibody 
(Fig. l a). In Jurkat cells 4 and 6 h after treatment with 
anti-Fas antibody, a 160-kDa polypeptide (pl60) was ob- 
served in addition to 460-kDa DNA-PKcs (p460). Since a 
faint immunostain band of pl60 also appeared 2 h after the 
treatment, the appearance of pl60 seems to be earlier than the 
detection of the DNA ladder (Fig. lb). Apopain, a thiol pro- 
teinase involved in apoptosis, was induced slightly at 2 h and 
drastically at 4-6 h under treatment with anti-Fas antibody 
(Fig. lc). These results suggest hat p460 is cleaved by apo- 
pain during Fas-mediated apoptosis in Jurkat cells. DNA-PK 
activity in the crude extracts from Jurkat cells was essentially 
constant 0-4 h after treatment with anti-Fas antibody, and 
slightly decreased at 6 h (Fig. Id). Since the cleavage of 
DNA-PKcs resulted in decrease of the catalytic activity in 
vitro (see below), this may reflect the fact that a small propor- 
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tion of DNA-PK in apoptotic Jurkat cells is susceptible to 
digestion with apopain. 
To determine whether DNA-PKcs is one of the death sub- 
strates during Fas-mediated apoptosis, we directly tested 
whether DNA-PKcs is sensitive to digestion with apopain. 
As the DNA-PK holoenzyme consists of DNA-PKcs, Ku pro- 
tein and double-stranded DNA, the DNA-PK preparation 
purified from Raji cells was incubated in the presence of 
calf thymus DNA with different amounts of recombinant apo- 
pain. Silver staining of the digests showed 230- (p230) and 
160-kDa polypeptides (pl60) derived from p460 in a dose- 
dependent manner (Fig. 2a). In the absence of DNA, a similar 
result was obtained (data not shown). In this preparation of 
DNA-PK containing approximately equimolar DNA-PKcs 
(p460) and Ku protein (p70/p80), p80 and p70 were hardly 
detectable during the silver staining probably because of the 
great difference in their molecular masses. To confirm that 
apopain itself cleaves p460, recombinant apopain was prein- 
cubated with a potent peptide aldehyde inhibitor, Ac-DEVD- 
CHO. Under these conditions, cleavage of p460 was comple- 
tely inhibited (Fig. 2b), indicating the direct involvement of 
apopain in the digestion of p460 in vitro. 
We next investigated the relationship between the cleavage 
of DNA-PKcs with apopain and DNA-PK activity. As indi- 
cated in Fig. 2b, DNA-PK activity was decreased in propor- 
tion to the digestion of p460, and the reduction in activity was 
restored by preincubation with Ac-DEVD-CHO. Since the 
DNA-PK activity is largely dependent on the Ku DNA-bind- 
ing component that recruits DNA-PKcs to double-stranded 
DNA, it is important to establish whether DNA-PKcs, Ku 
protein or both are responsible for the decrease in DNA-PK 
activity on incubation with apopain. Immunostaining with 
anti-DNA-PKcs and anti-Ku antibodies after incubation of 
DNA-PK with recombinant apopain revealed that DNA- 
PKcs (p460) was cleaved into p230 and pl60 (Fig. 3a), and 
Ku (p70/p80) was not significantly affected (Fig. 3b). These 
observations revealed that only DNA-PKcs is sensitive to di- 
gestion with apopain in DNA-PK holoenzyme composed of 
DNA-PKcs, a regulatory component Ku protein (p70/pS0) 
and a cofactor double-stranded DNA. 
4. Discussion 
DNA-PK activity was substantially decreased with disap- 
pearance of DNA-PKcs after incubation of DNA-PK holoen- 
zyme with a thiol proteinase apopain (Fig. 2b). In contrast, 
we observed only a slight decrease in activity of DNA-PK in 
crude extracts from apoptotic Jurkat cells (Fig. ld). This is 
likely to imply that a small proportion of DNA-PKcs was 
cleaved in apoptotic Jurkat cells (see Fig. la). Human cells 
and tissues contain a large number of DNA-PKcs as in the 
case of Ku protein abundant in higher organisms, so that 
DNA-PK activity in human cells has been reported to be 
approximately two-orders higher than that in rodent cells ex- 
hibiting a quite low activity of DNA-PK (see [33]). A small 
proportion of p460 may be functional in Jurkat cells derived 
from human T lymphocytes, which is presumably susceptible 
to digestion with apopain under apoptosis. 
Two polypeptides with molecular masses of approx. 230 
kDa (p230) and 160 kDa (pl60) derived from DNA-PKcs 
(p460) were detected by silver staining. In apoptotic Jurkat 
cells, however, pl60 alone was observed and p230 was hardly 
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Fig. 1. Cleavage of DNA-PKcs by treatment of Jurkat cells with anti-Fas antibody. Jurkat cells were treated with anti-Fas antibody (100 ng/ 
ml) for 0 (lane 1), 2 (lane 2), 4 (lane 3) and 6 h (lane 4). (a) The whole cell extracts from 4× 105 cells were subjected to electrophoresis on 
0.1% SDS/4-20% polyacrylamide gradient gel, followed by imrnunostaining with anti-DNA-PKcs antibody. Myosin (200 kDa) and phosphory- 
lase b (94 kDa) are indicated as marker polypeptides. DNA-PKcs (p460) and the cleaved polypeptide (p160) are indicated by arrows. (b) DNA 
from the anti-Fas treated Jurkat cells was subjected to electrophoresis on 2% agarose gel/0.5×TBE/1 ~tg m1-1 ethidium bromide. ~,DNA di- 
gested with HindlII was used as a marker. (c) The activity of apopain in 2.5- and 5-p.1 aliquots of the whole cell extracts was determined with 
Ac-DEVD-AMC as a substrate. The released AMC was fluorometrically detected. (d) DNA-PK activity in a 3 ktl portion of the whole cell ex- 
tracts was determined with a substrate peptide 15 (black bars) and mutant peptide 15 (shaded bars). 
detectable in immunoblot analysis of the whole cell extracts 
(Fig. la). This does not seem to be incompatible because p230 
was less immunoreactive with the rabbit anti-DNA-PKcs anti- 
body than p160 (see Fig. 3a). DNA-PKcs seems to be a death 
substrate susceptible to proteolytic leavage by apopain dur- 
ing the Fas-mediated apoptotic process. A DNA-binding 
component Ku protein composed of 70- and 80-kDa poly- 
peptides was not significantly susceptible to the digestion with 
apopain. No cleavage of Ku protein was observed in anti-Fas- 
treated Jurkat cells (data not shown). This is consistent with 
the observation with UV-irradiated HeLa cells [23], but seems 
to stand in contrast o the result demonstrating decreased 
levels of Ku protein during apoptosis in HL-60 and peripheral 
blood lymphocytes [34]. 
Apopain specifically induces cleavage of poly(ADP-ribose) 
polymerase, which occurs at the onset of apoptosis, and a 
potent peptide aldehyde inhibitor of apopain prevents apop- 
tosis in vitro [24-26]. The cleavage site in poly(ADP-ribose) 
polymerase is DEVD216-G217, and there are six D-G sites 
within p460 [1]: PCLD797-G798, GDSD2020-G2021, 
QTAD2650-G2651, DWVD2982-G2983, VDQD3210-G3211 
and GQYD3705-G3706. In order to determine the cleavage 
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Fig. 2. Treatment of DNA-PK with recombinant apopain. After incubation of DNA-PK with apopain in a 20 tal reaction mixture containing 
0.4 ~tg calf thymus DNA, 5-1.0 portions of the reaction mixture were used for determination of DNA-PK activity, and the residues were sub- 
jected to electrophoresis on 0.1% SDS/7.5% polyacrylamide gel with subsequent sliver staining. DNA-PKcs (p460) and its limited-degradation 
products (p230 and p160) are indicated by arrows. Myosin (200 kDa), 13-galactosidase (116 kDa), phosphorylase b (94 kDa), bovine serum al- 
bumin (67 kDa) and ovalbumin (43 kDa) were used as marker polypeptides. (a) The purified preparation of DNA-PK (280 ng) was incubated 
with the indicated amount of recombinant apopain (lanes 1-5) at 30°C for 30 min. Lane 6, without DNA-PK; lane 7, buffer alone. (b) Apo- 
pain was preincubated with Ac-DEVD-CHO (100 p.M) at 30°C for 10 min (lanes 4-45), followed by addition of DNA-PK. After incubation of 
DNA-PK in a total volume of 20 lxl, 0.2 I.tl of 10 mM Ac-DEVD-CHO was added to the reaction mixture to inactivate apopain (lanes 1-3). 
Lane 7, apopain alone. DNA-PK activity expressed as pmol Pi incorporated into peptide 15 per min at 30"C is indicated below the lanes. 
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Fig. 3. Western blot/enzyme immunoassay of DNA-PK after treat- 
ment with apopain. (a) The purified DNA-PK (280 ng) was incu- 
bated with the indicated amount of apopain at 30°C for 30 min in 
a 20 ~1 reaction mixture containing 0.4 l.tg calf thymus DNA (lanes 
14). Apopain was preincubated with Ac-DEVD-CHO (100 I~M) at 
30°C for 10 min (lane 4). The reaction products were subjected to 
electrophoresis on 0.1% SDS/7.5% polyacrylamide g l. Immunoblot 
analysis was performed with rabbit anti-DNA-PKcs antibody. (b) 
The purified DNA-PK (280 ng) was incubated with the indicated 
amount of apopain (lanes 1-3) and the reaction products were ana- 
lyzed as in (a) with human anti-Ku serum (OM) instead of anti- 
DNA-PKcs antibody. 
sites within DNA-PKcs, it may be necessary to perform mi- 
cro-sequencing of p230 and p160. Considering the molecular 
mass of p230, we now estimate GDSD2020-G2021 as one of 
the cleavage sites in p460. Enari et al. [30] recently reported 
sequential activation of ICE-like proteinase and CPP32-1ike 
proteinase (=apopain) during Fas-mediated apoptosis in 
mouse transforrnant T cells expressing exogenous Fas, and 
induction of apoptosis in intact nuclei from mouse liver by 
addition of apopain together with the cytoplasmic ompo- 
nent(s). Accumulating lines of evidence including this report 
to date demonstrate hat apopain is responsible for the spe- 
cific cleavage of poly(ADP-ribose) polymerase and DNA- 
PKcs early during the apoptotic process. It is especially inter- 
esting that poly(ADP-ribose) polymerase and DNA-PK have 
common characteristics including the requirement of DNA 
for enzymatic activity, involvement in the repair process, early 
cleavage during the apoptotic process and a target for auto- 
antibody in autoimmune disease [23,31]. 
Since DNA-PK appears to be involved at least in double- 
strand break repair as well as V(D)J recombination [14-20], a 
functional significance in apoptotic degradation of DNA- 
PKcs would be to prevent rejoining fragmented DNA during 
the apoptotic process. Specific inhibitors of DNA-PK, such as 
OK-1035 [21,22], or mutant cells devoid of DNA-PK activity, 
such as mouse scid cells, may be useful for confirming the 
significance of DNA-PK in the apoptotic process. 
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